Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Appointed CFO
Director departure
Appointed director
ROCK CREEK PHARMACEUTICALS, INC. (RCPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2016 8-K Quarterly results
08/29/2016 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
08/17/2016 8-K Submission of Matters to a Vote of Security Holders
08/10/2016 10-Q Quarterly Report for the period ended June 30, 2016
07/22/2016 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/11/2016 PRE 14A Form PRE 14A - Other preliminary proxy statements
07/08/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Interim Note Agreement"
07/08/2016 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
05/16/2016 10-Q Quarterly Report for the period ended March 31, 2016
04/29/2016 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
04/29/2016 10-K/A Annual Report for the period ended December 31, 2015 [amend]
04/13/2016 D Form D - Notice of Exempt Offering of Securities
04/06/2016 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
03/31/2016 4 Scannell Robert (Director) has filed a Form 4 on ROCK CREEK PHARMACEUTICALS, INC.
Txns: Bought 285,714 shares @ $0.35, valued at $100k
Bought 571,428 warrants @ $1.12, valued at $640k
03/31/2016 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Common Stock Purchase Warrant, issued by Rock Creek Pharmaceuticals, Inc. to Investors under the Securities Purchase Agreement",
"Form of Securities Purchase Agreement, among Rock Creek Pharmaceuticals, Inc. and the Investor(s) a party thereto"
03/28/2016 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
03/22/2016 8-K Quarterly results
Docs: "Rock Creek Pharmaceuticals Announces 2015 Annual Results and Provides Commentary and Review"
03/22/2016 10-K Annual Report for the period ended December 31, 2015
02/17/2016 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
02/12/2016 EFFECT Form EFFECT - Notice of Effectiveness
02/04/2016 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
12/15/2015 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend]
11/25/2015 4 Scannell Robert (Director) has filed a Form 4 on ROCK CREEK PHARMACEUTICALS, INC.
Txns: Granted 2,000 options to buy @ $0.87, valued at $1.7k
11/13/2015 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933
11/09/2015 10-Q Quarterly Report for the period ended September 30, 2015
08/10/2015 10-Q Quarterly Report for the period ended June 30, 2015
06/17/2015 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]
06/17/2015 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]
05/12/2015 10-Q Quarterly Report for the period ended March 31, 2015
03/12/2015 DEF 14A Form DEF 14A - Other definitive proxy statements
03/12/2015 10-K Annual Report for the period ended December 31, 2014
02/13/2015 SC 13G PV Partners LP reports a 5.6% stake in ROCK CREEK PHARMACEUTICALS, INC.
11/10/2014 10-Q Quarterly Report for the period ended September 30, 2014
10/17/2014 DEF 14A Form DEF 14A - Other definitive proxy statements
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy